Trial Profile
Head-to-head Comparison of Quadruple Combination Therapy With Empagliflozin and Dapagliflozin in Patients With Poorly Controlled Type 2 Diabetes (T2D) Despite Three Existing Oral Antidiabetic Drugs (OAD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jul 2022
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Empagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 19 Jul 2022 Status changed from active, no longer recruiting to completed.
- 01 Dec 2021 Results assessing the long-term (3-year) effectiveness and safety of two distinct sodium-glucose co-transporter 2 (SGLT2) inhibitors, empagliflozin and dapagliflozin, in inadequately controlled type 2 diabetes (T2D) despite a combined administration of metformin, glimepiride and dipeptidyl peptidase-4 inhibitor, published in the Diabetes Research and Clinical Practice.
- 02 Nov 2021 Planned End Date changed from 30 Jun 2021 to 30 Dec 2021.